Biomarker ID | 362 |
PMID | 18593988 |
Year | 2008 |
Biomarker | IL8 + Osteopontin |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Recurrent Group |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(CXCL8):-Cytokines and inflammatory response,FRA pathway, PERK-regulated gene expression,Interleukin-7 interactions in immune response,Corticotropin releasing hormone pathway |
Experiment | Reccurance Free Survival Vs Recurrance in 5 years |
Type of Biomarker | Prognostic |
Cohort | 103 prostatectomy specimens were obtained with a 72 month follow up period. 53 cases of Biochemical reccurrances and 50 patients with no recurrance. |
Senstivity | 95% (Monte Carlo Cross Validation 86 ± 8.5%) |
Specificity | 65% (Monte Carlo Cross Validation 60.5 ± 6.5%) |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.001 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | CXCL8, SPP1 |